AbbVie (NYSE:ABBV) Updates FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 13.910-14.110 for the period, compared to the consensus EPS estimate of 14.250. The company issued revenue guidance of -. AbbVie also updated its Q2 2026 guidance to 3.570-3.610 EPS.

AbbVie Stock Performance

Shares of ABBV opened at $252.98 on Thursday. The company has a market capitalization of $446.96 billion, a price-to-earnings ratio of 124.62, a PEG ratio of 0.84 and a beta of 0.30. The company’s 50 day simple moving average is $223.50 and its 200 day simple moving average is $220.90. AbbVie has a 1 year low of $184.63 and a 1 year high of $261.64.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.46 EPS. Equities analysts expect that AbbVie will post 14.19 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is currently 340.89%.

Analyst Ratings Changes

Several research firms recently commented on ABBV. Guggenheim reiterated a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Piper Sandler reaffirmed an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Evercore set a $235.00 price objective on shares of AbbVie in a report on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.67.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved AbbVie’s Tepkinly in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, expanding the drug’s commercial opportunity in Europe and reinforcing AbbVie’s oncology growth pipeline. EC approves AbbVie’s Tepkinly combination for follicular lymphoma
• Positive Sentiment: AbbVie completed a first-in-human study for ABBV-277, a clinical-stage program that could provide additional safety and efficacy data for investors watching the company’s next wave of pipeline assets. AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors
• Neutral Sentiment: AbbVie’s upcoming second-quarter earnings report is expected to show double-digit EPS growth, but investors are focused on whether results can offset recent concerns around forward guidance and margin trends. AbbVie Earnings Preview: What to Expect
• Negative Sentiment: AbbVie lowered its FY 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, and also guided Q2 EPS to $3.57-$3.61 versus expectations of $3.77, which is likely weighing on the shares today.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. raised its holdings in AbbVie by 38.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 25,847 shares of the company’s stock valued at $5,906,000 after buying an additional 7,116 shares during the period. Strive Financial Group LLC purchased a new stake in AbbVie during the fourth quarter worth approximately $216,000. Blue Sparrow LLC DE purchased a new stake in AbbVie during the fourth quarter worth approximately $28,561,000. Mercer Global Advisors Inc. ADV increased its position in shares of AbbVie by 5.9% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 430,631 shares of the company’s stock worth $100,411,000 after acquiring an additional 23,859 shares in the last quarter. Finally, Summit Global Investments raised its stake in shares of AbbVie by 21.4% in the 4th quarter. Summit Global Investments now owns 16,916 shares of the company’s stock valued at $3,865,000 after acquiring an additional 2,987 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.